Are you for the cabergoline price online?
Cabergoline price- Firstly, cabergoline is a white powder soluble in ethyl alcohol, chloroform, and N, N-dimethylformamide (DMF); slightly soluble in 0.1N hydrochloric acid; very slightly soluble in n-hexane; and insoluble in water.
DOSTINEX Tablets, for oral administration, contain 0.5 mg of cabergoline. Inactive ingredients consist of leucine, USP, and lactose, NF.
DOSAGE AND ADMINISTRATION
The recommended dosage of DOSTINEX Tablets for initiation of therapy is 0.25 mg twice a week. Also, dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. In addition, before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease.
Dosage increase should not occur more rapidly than every 4 weeks, so that the physician can assess the patient’s response to each dosage level.Therefore, if the patient does not respond adequately, and we can’t see any additional benefit with higher doses, the lowest dose with maximal response should can go and other therapeutic approaches too.In addition, Patients receiving long term treatment with DOSTINEX should undergo periodic assessment of their cardiac status and echocardiography.
Furthermore, after a normal serum prolactin level can maintain for 6 months,at this time, we can stop taking DOSTINEX, with periodic monitoring of the serum prolactin level to determine whether or when treatment with DOSTINEX should start.
DOSTINEX Tablets is a white, score, capsule-shape tablets containing 0.5 mg cabergoline. Also, each tablet is score on one side and has the letter P and the letter U on either side of the breakline. In addition, the other side of the tablet is engrave with the number 700.
DOSTINEX is available as follows:
Bottles of 8 tablets NDC 0013-7001-12
Store at controlled room temperature 20°to 25°C (68°to 77°F) [see USP].
The safety of DOSTINEX Tablets is in more than 900 patients with hyperprolactinemic disorders. Most adverse events were mild or moderate in severity.
In a 4-week, double-blind, placebo-controlled study, treatment consisted of placebo or cabergoline at fixed doses of 0.125, 0.5, 0.75, or 1.0 mg twice weekly.
Other adverse events that were reported at an incidence of < 1.0% in the overall clinical studies follow.
Metabolic and Nutritional System: weight loss, weight gain
Skin and Appendages: acne, pruritus
Special Senses: abnormal vision
Urogenital System: dysmenorrhea, increased libido
The safety of cabergoline has been evaluated in approximately 1,200 patients with Parkinson’s disease in controlled and uncontrolled studies at dosages of up to 11.5 mg/day which greatly exceeds the maximum recommended dosage of cabergoline for hyperprolactinemic disorders. In addition to the adverse events that occurred in the patients with hyperprolactinemic disorders, the most common adverse events in patients with Parkinson’s disease were dyskinesia, hallucinations, confusion, and peripheral edema.Furthermore, Heart failure, pleural effusion, pulmonary fibrosis, and gastric or duodenal ulcer occurred rarely. One case of constrictive pericarditis has been reported.
Postmarketing Surveillance Data
The following events have been reported in association with DOSTINEX: cardiac valvulopathy and extracardiac fibrotic reactions, (See WARNINGS, Cardiac Valvulopathy and Extracardiac Fibrotic Reactions).
Other events have been reported in association with cabergoline: hypersexuality, increased libido and pathological gambling (See PRECAUTIONS, Psychiatric). In addition, cases of alopecia, aggression and psychotic disorder have been reported in patients taking DOSTINEX. Also, some of these reports have been in patients who have had prior adverse reactions to dopamine agonist products.